ライフサイエンスコーパス: CAR

1 ed alongside images of non-food distractors (cars).

2 the trityl radical Ph(3)C. to give Ph(3)C-C=CAr.

3 second-generation CAR targeting Igkappa, IGK CAR.

4 studying the overlapping function of PXR and CAR.

5 ugh the randomized presence of a high-status car.

6 set of larger adamantane wheels on the same car.

7 fragment (scFv) used clinically in anti-BCMA CARs.

8 nhancers increased, whereas AR was lost from cAREs.

9 oundary building; and the role of empathy in caring.

10 adoptive transfer than do CD28-costimulated CAR (28zeta) T cells.

11 rs were activated by purified R. sphaeroides CarD, a transcription factor found in many bacterial spe

12 onavirus Aid, Relief, and Economic Security (CARES) Act.

13 ll persistence even in the context of 28zeta CAR activation, which indicates distinct prosurvival sig

14 i (R' = aryl, silyl) and Ph-Li to [Cu(II)]-C=CAr affords the corresponding C(sp)-C(sp) and C(sp)-C(sp

15 [Cu(II)]-C=CAr also captures the trityl radical Ph(3)C. to give Ph(

16 In addition, CAR altered sterol metabolism in all animals analyzed, w

17 en objects of the same kind (e.g., different cars), an effect never reported before with spoken langu

18 forms to the Glaser coupling product ArC=C-C=CAr and [Cu(I)](solvent).

19 pha bridging the PBREM and OARE orchestrates CAR and HNF4alpha to form active chromatin complex durin

20 The 19-CAR and ML responses were synergistic and CAR specific a

21 abundant-reticular (CAR) cell subsets (Adipo-CAR and Osteo-CAR) differentially localize to sinusoidal

22 sp) and C(sp)-C(sp2) coupled products RC=C-C=CAr and Ph-C=CAr with concomitant generation of [Cu(I)](

23 we describe updates and recent expansions to CARD and its biocuration process, including new resource

24 Baseline models were CARES and ASA-PS.

25 Helping nurses to be proactively more self-caring and self-compassionate may increase their ability

26 n from others and from themselves to be self-caring and self-compassionate.

27 rbital via constitutive androstane receptor (CAR) and hepatocyte nuclear factor 4 alpha (HNF4alpha).

28 6-ACA and HMD by carboxylic acid reductases (CARs) and transaminases (TAs), which involves two rounds

29 Our results demonstrate that a combinatorial CAR approach can improve target selectivity and efficacy

30 effective, but a chimeric antigen receptor (CAR) approach would provide a feasible method for broad

31 ree-coordinate copper(II) alkynyl [Cu(II)]-C=CAr (Ar = 2,6-Cl(2)C(6)H(3)) forms upon reaction of the

32 These cars are designed to be stimulated with an electric fiel

33 l UK NH(3) emissions from gasoline passenger cars are estimated to be 7.8 +/- 0.3 kt from the bottom-

34 Anti-CD19 chimeric antigen receptors (CARs) are artificial fusion proteins that cause CD19-spe

35 p music, novels, the clinical literature and cars-as well as a collection of organic populations.

36 ) and its effector, MAPK Sty1, downregulates CAR assembly in S. pombe when its integrity becomes comp

37 iven by a cell polarity kinase that promotes CAR assembly in the correct time and place.

38 4-1BB-costimulated CAR (BBzeta) T cells exhibit longer persistence after ad

39 We also measured CAR bioaccessibility by using an in vitro model.

40 c Resistance Ontology (ARO), designed by the CARD biocuration team to integrate with software develop

41 data, we create a 'targetable landscape' for CAR cell therapies based on 13,206 proteins and RNAs acr

42 demonstrate that Cxcl12-abundant-reticular (CAR) cell subsets (Adipo-CAR and Osteo-CAR) differential

43 er the levels and distribution of cohesin at CARs, changing the pattern of positioned loops.

44 treatment using immune check inhibitors and CAR (chimeric antigen receptor) T-cell therapy serve as

45 as to enhance provitamin A carotenoid (proVA CAR) concentrations and bioaccessibility in carrots by m

46 ses to maintain people's identity, establish caring connections and ensure that individual patient ne

47 tes in a checkpoint, capable of triggering a CAR constriction delay through the SIN pathway to ensure

48 mporal coordination between actomyosin ring (CAR) constriction with membrane ingression and septum sy

49 Differential signaling through the CAR costimulatory domain can alter the T cell metabolism

50 a decrease in numbers of opioid-overdose and car-crash deaths compared with what would have been expe

51 We analyzed state identification card demographic and organ donor registration data from

52 d sleep and the cortisol awakening response (CAR), depending on whether it was experienced or just an

53 e engraftment persistence observed with this CAR design.

54 A CAR designated FHVH33-CD8BBZ contains a fully human heav

55 ular (CAR) cell subsets (Adipo-CAR and Osteo-CAR) differentially localize to sinusoidal and arteriola

56 erization domain-like receptors (NLR) family CARD domain-containing 5 (NLRC5), in patients and mice w

57 s with consensus androgen response elements (cAREs) drive proliferation but genes with selective elem

58 maging even in very extreme conditions (race car driving) to study the sensory inputs, motor outputs,

59 Furthermore, CAR elevated toxic oxysterols in the brain of maternally

60 Thus, CAR engineering of ML NK cells enhanced responses agains

61 We hypothesized that ML differentiation and CAR engineering would result in complementary improvemen

62 n visual stimuli depicting specific objects (cars, faces, and buildings) and changes in attention to

63 nd suggests similar regulatory mechanisms in caring females and males.

64 position fluorescence in situ hybridization (CARD-FISH) on >14 500 archaeal and bacterial cells (Meth

65 CARD focuses on providing high-quality reference data an

66 Physicians in the highest risk quintile cared for 52.0% of dually eligible patients; those in th

67 access to a carcass, whilst females that had cared for a large brood were similar in competitive abil

68 nitial breeding attempt, as females that had cared for a small brood were better competitors than vir

69 Patients cared for at the most disadvantaged-serving practices (g

70 contained information on 2,898,505 patients, cared for by 4,859 providers in 431 practices.

71 contained information on 6,040,996 patients, cared for by 8,853 providers in 724 practices.

72 The number of ICU patients cared for by each resident physician was higher during s

73 no more likely to acquire MRSA if they were cared for using standard precautions versus contact prec

74 oral and physiological adaptations to enable caring for offspring, but the underlying CNS changes are

75 s us of the importance of mutual support and caring for our own mental health, including seeking help

76 QOL should be considered when counseling and caring for patients undergoing esophagectomy.

77 curately comparing countries' performance in caring for patients with COVID-19 and for monitoring the

78 Domestic providers caring for SIVH should follow the US Centers for Disease

79 ive symptoms when older individuals are also caring for their grandchildren.

80 hes are similar, making the relative cost of caring for these patients over time an important conside

81 and our clinical experience, we propose the CARES framework to guide care for caregivers in oncology

82 nt mice were exposed to vehicle or 0.2 mg/kg CAR from E12 to E19.

83 The clinical study of PD-L1 CAR haNKs is warranted.

84 PD-L1 CAR haNKs reduced levels of macrophages and other myeloi

85 o express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and n

86 Since 2017, CARD has expanded through extensive curation of referenc

87 rial of T cells expressing the new anti-CD19 CAR Hu19-CD828Z (NCT02659943).

88 resistance using the information included in CARD, identify trends in AMR mobility and determine prev

89 e and coherent anti-Stokes Raman scattering (CARS) imaging of the sciatic nerve, we deciphered the sp

90 second-generation chimeric antigen receptor (CAR) improved antitumor activity of CAR-T cells.

91 ProVA CAR in carrots with the highest concentrations also prov

92 uture evaluation in other CD28-costimulatory CARs in an effort to improve durable antitumor effects.

93 Overall, CarD increased the activity of 15 of 16 native R. sphaer

94 ector expressing genes that encode anti-CD19 CAR, interleukin-15, and inducible caspase 9 as a safety

95 ovides further evidence to indicate that the CAR is a marker of anticipation and not recovery.

96 CarD is required for MTB viability and it has highly con

97 However, coexpression of endogenous TCR plus CAR led to superior persistence of T cells and significa

98 CAR macrophages (CAR-Ms) demonstrated antigen-specific p

99 continuity or architecture, or on any Day 3 CAR measure.

100 minutes on each subsequent day (Day 1-3) and CAR measurement indices were derived: awakening cortisol

101 maintaining common activation mechanisms of CARD-mediated dimerization.

102 However, CARD-mediated multimerization also makes Aire susceptibl

103 19-CAR-ML NK cells controlled lymphoma burden in vivo and i

104 Furthermore, 19-CAR-ML NK cells generated from lymphoma patients exhibit

105 uding those using chimeric antigen receptor (CAR)-modified T cells, to solid tumors requires combinat

106 s support the therapeutic potential of CD147-CAR-modified immune cells for HCC patients.

107 In humanized mouse models, CAR-Ms were further shown to induce a pro-inflammatory t

108 CAR macrophages (CAR-Ms) demonstrated antigen-specific phagocytosis and t

109 ethodologies confirm that gasoline passenger car NH(3) emissions are underestimated by a factor of ab

110 al, we administered HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood to 11 patients with

111 The infused CAR-NK cells expanded and persisted at low levels for at

112 of three doses (1x10(5), 1x10(6), or 1x10(7) CAR-NK cells per kilogram of body weight) after lymphode

113 f concept of targeting TF as a new target in CAR-NK immunotherapy for effective treatment of TNBC and

114 ogic adverse events, as they occurred before CAR-NKT cell infusion, and no dose-limiting toxicities w

115 CAR-NKT cells expanded in vivo, localized to tumors and,

116 /- 3.8%) and treated patients with 3 x 10(6) CAR-NKT cells per square meter of body surface area afte

117 trials employing chimeric antigen receptors (CARs), no comprehensive survey of their scope, targets a

118 In this study, negatively charged CAR-NPs and positively charged polyethylenimine (PEI)-co

119 l and motor patterns while he drove a sports car on the "Top Gear" race track under extreme condition

120 cases in which a pedestrian was killed by a car operated under shared control of a primary and a sec

121 ier that delivers in vitro-transcribed (IVT) CAR or TCR mRNA for transiently reprograming of circulat

122 rmats of whole genome sequences based on the CARD or ResFinder databases.

123 tively charged polyethylenimine (PEI)-coated CAR-(PEI)NPs were formulated by nanoprecipitation method

124 Median peak blood CAR-positive cell levels were higher among patients with

125 Moreover, CAR preferably interacted with phosphomimetically mutate

126 Taken together, the BCMA/CS1 bispecific CAR presents a promising treatment approach to prevent a

127 r)(R) species that reductively eliminate R-C=CAr products.

128 , redox disproportionation forms [Cu(III)](C=CAr)(R) species that reductively eliminate R-C=CAr produ

129 eneration of [Cu(I)](solvent) and {[Cu(I)]-C=CAr}(-), respectively.

130 r resistome analysis and prediction, such as CARD's Resistance Gene Identifier (RGI) software.

131 LogCD147-CAR selectively kills dual antigen (GPC3(+)CD147(+)), bu

132 Embryonic exposure to CAR significantly increased levels of 7-DHC in all organ

133 In solution, this [Cu(II)]-C=CAr species cleanly transforms to the Glaser coupling pr

134 19-CAR and ML responses were synergistic and CAR specific and required immunoreceptor tyrosine-based

135 up-regulated in type 1 diabetic Akita mice; CAR spontaneously accumulates in the nucleus and activat

136 report the quality-of-life outcomes from the CARD study.

137 , we determined the crystal structure of the CAR substrate-binding domain in complex with AMP and suc

138 f lipid extrusion, distinct from the 'credit card swipe' model of other lipid transporters.

139 We further demonstrated that the CAR synapse can be engineered to recruit either LCK to e

140 nch (Taeniopygia guttata), with a biparental caring system.

141 weeks to generate GBOs and 5-7 d to perform CAR T cell co-culture using this protocol.

142 Perforin contributed to both CD8+ and CD4+ CAR T cell cytotoxicity but was not required for in vitr

143 vestigated the role of perforin in anti-CD19 CAR T cell efficacy and HLH-like toxicities in a syngene

144 esponse might serve as an early predictor of CAR T cell efficacy.

145 ch as IL-1beta and IL-18 and concurrent late CAR T cell expansion characterized the HLH-like syndrome

146 ty in the cellular and molecular features of CAR T cell infusion products contributes to variation in

147 ptor (CAR) T cell therapy is correlated with CAR T cell persistence, especially for CAR T cells that

148 enhanced therapeutic potency of a novel Dual-CAR T cell product with the potential to effectively tre

149 Through iterative improvements to the CAR T cell product, we developed Dual-CAR T cells that s

150 , we discuss the innovative designs of novel CAR T cell products that are being developed to increase

151 t inflammatory toxicities occurring in human CAR T cell recipients, providing therapeutically relevan

152 ccur after chimeric antigen receptor T cell (CAR T cell) infusion and represent a therapeutic challen

153 CAR T cells administered ICV also traffic from the CNS i

154 ing clearance of ATRT xenografts, B7-H3.BB.z-CAR T cells administered intracerebroventricularly or in

155 fraction of patients who received anti-CD22 CAR T cells also experienced biphasic inflammation, with

156 R T cells had greater ex vivo expansion than CAR T cells and killed CD19+ leukemic cells more effecti

157 However, CAR T cells can induce substantial toxic effects, and th

158 oluminescence and PET imaging of B7H3-sr39tk CAR T cells confirmed complete tumor ablation with intra

159 ll modifications, redosing or combination of CAR T cells directed against different targets, and decr

160 ross-presentation, that CD40L-overexpressing CAR T cells elicit an impaired antitumor response in the

161 oints after infusion.CONCLUSIONSB-engineered CAR T cells expand and persist in pediatric and adult B-

162 al. report favorable ZUMA-2 trial results of CAR T cells for patients with relapsed and refractory ma

163 Nevertheless, the use of allogeneic CAR T cells from donors has many potential advantages ov

164 Three cycles of HER2 CAR T cells given after lymphodepleting chemotherapy ind

165 In the presence of Epo, EpoRm-CAR T cells had greater ex vivo expansion than CAR T cel

166 sociated antigen enables robust expansion of CAR T cells in an antigen-sparse environment.

167 st study to show expansion of virus-specific CAR T cells in infected, suppressed hosts, and delay/con

168 Key challenges relating to CAR T cells include severe toxicities, restricted traffi

169 However, allogeneic CAR T cells may cause life-threatening graft-versus-host

170 e stimulatory effect of CD40L-overexpressing CAR T cells on innate and adaptive immune cells, and pro

171 Thus, a murine model of perforin-deficient CAR T cells recapitulated late-onset inflammatory toxici

172 In comparison to CAR T cells, p40-Td CAR T cells showed improved antitumor capacity in vitro,

173 In addition, while CD229 CAR T cells target normal CD229(high) T cells, they spar

174 Here, we develop CD229 CAR T cells that are highly active in vitro and in vivo

175 to the CAR T cell product, we developed Dual-CAR T cells that simultaneously expressed both 4-1BB/CD3

176 with CAR T cell persistence, especially for CAR T cells that target CD19(+) hematologic malignancies

177 CAR T cells that target uPAR extend the survival of mice

178 e a rationale for using CD40L-overexpressing CAR T cells to improve immunotherapy responses.

179 tional assays for quantifying the ability of CAR T cells to sense and respond to soluble ligands are

180 based on gene editing, to produce allogeneic CAR T cells with limited potential for graft-versus-host

181 In comparison to CAR T cells, p40-Td CAR T cells showed improved antitumo

182 In 2 animals with declining CAR T cells, rhesusized anti-programmed cell death prote

183 ignaling in promoting the survival of BBzeta CAR T cells, which likely underlies the engraftment pers

184 re sufficient to preferentially expand EpoRm-CAR T cells, yielding a significantly higher antileukemi

185 and ex vivo culture system for CD19-specific CAR T cells.

186 recruit and potentiate the functionality of CAR T cells.

187 imaging reporter and as a suicide switch for CAR T cells.

188 patients were infused with a single dose of CAR T cells.

189 .CONCLUSIONIn this series of Allo, Auto, and CAR T recipients, we report overall favorable clinical o

190 nts of cellular therapy (Allo, 35; Auto, 37; CAR T, 5; median time from cellular therapy, 782 days; I

191 mphoma model without affecting CD19-specific CAR T-cell antitumor activity.

192 Various anti-CD19 CAR T-cell constructs have been trialled and responses v

193 ies, suggesting a link between mechanisms of CAR T-cell cytotoxicity and cancer genetics.

194 rtant mediator of cancer cell sensitivity to CAR T-cell cytotoxicity, with potential for pharmacologi

195 cer drugs and genetic mechanisms influencing CAR T-cell cytotoxicity.

196 Response consolidation with additional CAR T-cell infusions includes pembrolizumab to improve t

197 mission which is consolidated with four more CAR T-cell infusions without lymphodepletion.

198 selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heighten

199 We demonstrated recipient anti-CAR T-cell responses against a murine single-chain varia

200 Two CAR T-cell therapies, tisagenlecleucel and axicabtagene

201 re consistent with those reported with other CAR T-cell therapies.

202 ing T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.

203 CD19 CAR T-cell therapy with concurrent ibrutinib was well to

204 clinical outcomes and report on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies

205 rs occurred after 51% of evaluable anti-CD19 CAR T-cell treatments.

206 In the largest experience of CD22 CAR T-cells to our knowledge, we provide novel informati

207 s underwent leukapheresis for manufacture of CAR(+) T cells (liso-cel), of whom 269 patients received

208 man CD83-targeted chimeric antigen receptor (CAR) T cell for GVHD prevention.

209 oint blockade and chimeric antigen receptor (CAR) T cell therapeutic modalities.

210 Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic mal

211 nical response to chimeric antigen receptor (CAR) T cell therapy is correlated with CAR T cell persis

212 Chimeric antigen receptor (CAR) T cell therapy works by mechanisms distinct from th

213 ovel HIV-specific chimeric antigen receptor (CAR) T cell to target both HIV-infected CD4(+) T cells a

214 third generation Chimeric Antigen Receptors (CAR) T cells demonstrating specific cytolytic activity.

215 ogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product th

216 ents treated with chimeric antigen receptor (CAR) T cells or bispecific T cell engager (BiTE) antibod

217 Chimeric antigen receptor (CAR) T cells represent a potent new approach to treat ha

218 ed the utility of chimeric antigen receptor (CAR) T cells, expressing the CD4 ectodomain to confer sp

219 tumor activity of chimeric antigen receptor (CAR) T cells.

220 tegies to monitor chimeric antigen receptor (CAR) T-cell biodistribution and proliferation harbor the

221 Innovations in chimeric antigen receptor (CAR) T-cell immunotherapies are at the forefront of new

222 s, CD19-directed, chimeric antigen receptor (CAR) T-cell product.

223 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable activity in pat

224 (2020) develop chimeric antigen receptor (CAR)-T cells targeting uPAR, a novel senescent-cell mark

225 Chimeric antigen receptor (CAR)-T immunotherapy has yielded impressive results in s

226 ges, are promising alternatives to alphabeta CAR-T adoptive therapy.

227 dyl ester (CFSE) release assay and evaluated CAR-T cell activation through interferon gamma (IFN-gamm

228 We assessed CAR-T cell cytotoxicity using a carboxyfluorescein succi

229 CAR-T cell expansion in vivo was cell dose dependent.

230 c approach is often limited by the extent of CAR-T cell expansion in vivo.

231 ions in the costimulatory domain may enhance CAR-T cell persistence, warranting future evaluation in

232 netics, making variable contributions to the CAR-T cell pool after infusion.

233 t treatment, possible standardization of the CAR-T cell product, time for multiple cell modifications

234 These improved allogeneic CAR-T cell products will pave the way for further breakt

235 atment approach to prevent antigen escape in CAR-T cell therapy against MM, and the vertically integr

236 nt sources of T cells for optimal allogeneic CAR-T cell therapy and describe the different technologi

237 CAR-T cell therapy is effective for hematologic malignan

238 ibody engineering, antibody humanization and CAR-T cell therapy.

239 mples from chimeric antigen receptor T cell (CAR-T cell) therapy patients without washing away excess

240 indings are important for the improvement of CAR-T cell-based immunotherapy for human cancers.

241 n and hindered the persistence of CD28-based CAR-T cells and changing this asparagine to phenylalanin

242 Thus, CD4-MBL CAR-T cells are unable to eliminate the FDC-associated H

243 odifications to the costimulatory domains of CAR-T cells can enable longer persistence and thereby im

244 Whether HIV-specific CAR-T cells can recognize and eliminate the follicular d

245 CAR-T cells costimulated with 4-1BB or ICOS persist in x

246 ells and the FDC reservoir in vitro Although CAR-T cells eliminated CD4(+) T cells that express HIV,

247 Therapies using NPM1c CAR-T cells for the treatment of NPM1c(+)HLA-A2(+) AML m

248 RNA sequencing (scRNA-seq) to profile CD8(+) CAR-T cells from infusion products (IPs) and blood of pa

249 CAR-T cells have shown encouraging activity against recu

250 , which are then eradicated by CD19-specific CAR-T cells in immunodeficient and immunocompetent mouse

251 RB sequencing shows that clonal diversity of CAR-T cells is highest in the IPs and declines following

252 hance the kinetics of tumor killing of 4-1BB CAR-T cells or SHP1 to tune down cytokine release of CD2

253 o acid substitution in CD28-based mesothelin CAR-T cells results in improved persistence and function

254 In breast and lung cancer patients, CAR-T cells targeting the tumor-associated antigen recep

255 These drawbacks can be circumvented by CAR-T cells targeting tumour-specific driver gene mutati

256 CD4-MBL CAR-T cells were unresponsive to cell-free HIV or concen

257 eceptor (CAR) improved antitumor activity of CAR-T cells.

258 r SHP1 to tune down cytokine release of CD28 CAR-T cells.

259 agement for patients receiving CD19-targeted CAR-T cells: pre CAR-T-cell infusion, immediate post CAR

260 he Csk-recruiting ITAM of CD3epsilon reduced CAR-T cytokine production whereas the basic residue rich

261 (IPs) and blood of patients undergoing CD19 CAR-T immunotherapy.

262 e rich sequence (BRS) of CD3epsilon promoted CAR-T persistence via p85 recruitment.

263 and opportunities for novel applications of CAR-T therapy for the treatment of both haematological m

264 ell deconstruction of gene regulation during CAR-T therapy, leading to the discovery of cellular fact

265 K patient developed acute pancreatitis after CAR-T therapy.

266 unosuppressive agents was prohibited in most CAR-T trials effectively excluding patients with prior s

267 Chimeric antigen receptor-T (CAR-T) cell therapies can eliminate relapsed and refract

268 persistence of chimeric antigen receptor T (CAR-T) cells is a key characteristic associated with lon

269 high net state of immunosuppression prior to CAR-T-cell infusion coupled with unique acute and persis

270 lls: pre CAR-T-cell infusion, immediate post CAR-T-cell infusion, and long-term follow-up.

271 nts receiving CD19-targeted CAR-T cells: pre CAR-T-cell infusion, immediate post CAR-T-cell infusion,

272 stent insults to their immune function after CAR-T-cell infusion.

273 receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clini

274 r chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited.

275 a or lambda, we designed a second-generation CAR targeting Igkappa, IGK CAR.

276 f T cells expressing FMC63-28Z, an anti-CD19 CAR tested previously by our group, which contains murin

277 nstrument was deployed on a light rail train car that continuously traverses the Salt Lake Valley (SL

278 e integration of lentiviral vectors encoding CAR that direct tumor cell killing.

279 urther advances are required for solid tumor CAR therapy.

280 Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy f

281 naling differences between BBzeta and 28zeta CARs, they demonstrate the necessary and nonredundant ro

282 been observed earlier with diesel passenger cars; they are considered part of an abnormal emission c

283 a single scFv scaffold, that allows the same CAR to be tested for toxicity in mice and efficacy again

284 enetically engineered human macrophages with CARs to direct their phagocytic activity against tumors.

285 antibody 237 as a chimeric antigen receptor (CAR) to mediate recognition of mouse tumor cells that be

286 s its caspase activation recruitment domain (CARD) to form filamentous homo-multimers in vitro, and t

287 a caspase activation and recruitment domain (CARD) to promote multimerization.

288 bination with a second-generation retroviral CAR transduction including a 4-1BB costimulatory domain

289 apsed or refractory HL and administered CD30.CAR-Ts after lymphodepletion with either bendamustine al

290 mutations might not be ideal candidates for CAR use, especially if they are nursing, pregnant or pla

291 oherent anti-Stokes Raman scattering (FASTER CARS) using tip-enhanced techniques markedly improves th

292 tion of AA to HMD (via 6-ACA), the wild type CAR was combined with the L342E variant and two differen

293 By adding these resistance variants to CARD, we are able to summarize predicted resistance usin

294 To specifically study signal transduction by CARs, we developed a cell-free, ligand-based activation

295 Test images demonstrating roads and cars were used to determine increased awareness of perip

296 -C(sp2) coupled products RC=C-C=CAr and Ph-C=CAr with concomitant generation of [Cu(I)](solvent) and

297 )H(3)) forms upon reaction of the alkyne H-C=CAr with the copper(II) tert-butoxide complex [Cu(II)]-O

298 MP and succinate and engineered three mutant CARs with enhanced activity against 6-ACA.

299 This strategy provides CARs with Tn-peptide specificities, all based on a singl

300 ss a GD2-specific chimeric antigen receptor (CAR) with interleukin-15 in children with relapsed or re